Last updated: February 20, 2026
What is the drug identified by NDC 00641-6194?
NDC 00641-6194 corresponds to Ceritinib (trade name: Zykadia), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations. It is an ALK inhibitor approved by the FDA for first-line and subsequent treatment stages.
Market Landscape Overview
Current Market Size and Demand
- The global NSCLC market was valued at approximately USD 16.2 billion in 2022, with targeted therapies accounting for around USD 6.5 billion.
- Ceritinib, approved in 2014, has gained acceptance primarily for ALK-positive NSCLC patients who are resistant or intolerant to crizotinib.
- The drug’s patient population is limited to a subset with ALK gene rearrangements. Estimated prevalence of ALK-positive NSCLC is approximately 3-5% of all NSCLC cases.
Competitive Environment
| Drug Name |
Mechanism |
Market Share (2022) |
Approved Indications |
Launch Date |
Price (USD) per treatment course |
| Ceritinib (Zykadia) |
ALK inhibitor |
35% |
ALK-positive NSCLC after crizotinib |
2014 |
~$14,000 |
| Alectinib (Alecensa) |
ALK inhibitor |
40% |
First-line and resistant ALK-positive NSCLC |
2017 |
~$16,500 |
| Brigatinib (Alunbrig) |
ALK inhibitor |
15% |
Resistant ALK-positive NSCLC |
2017 |
~$16,000 |
Ceritinib faces competition primarily from Alectinib, which has higher prescribing rates in first-line settings.
Market Penetration Trends
- Alectinib's superior efficacy and tolerability led to increasing market share over Ceritinib.
- Ceritinib's sales declined post-2018, but it remains relevant for patients intolerant to other ALK inhibitors.
Price Projections: Current and Future
Current Pricing
- Wholesale Acquisition Cost (WAC): Approx. USD 14,000 per treatment course.
- Average patient out-of-pocket costs may vary depending on insurance coverage, with many patients paying USD 2,000–4,000.
Market Dynamics Impacting Price
- Patent status: Patents Expire around 2024-2026, opening potential for generic or biosimilar competition.
- Biosimilars and generics: No biosimilar currently exists; however, generic competitors could enter within 2-4 years, potentially reducing prices by 30-50%.
- Reimbursement policies: CMS, private insurers, and international health agencies influence accessible pricing.
Future Price Trends (2023–2030)
| Year |
Estimated Price per Course (USD) |
Assumptions |
| 2023 |
~$14,000 |
Post-market stability |
| 2025 |
~$12,000 |
Patent expiration influences reduction |
| 2027 |
~$8,000 |
Entry of generics/biosimilars, increased competition |
| 2030 |
~$6,000 |
Market penetration with cost-effective alternatives |
Key Factors Affecting Price Trajectories
- Patent expirations: Expected 2024–2026, with generic entry likely within 1-2 years afterward.
- Clinical updates: New, more effective ALK inhibitors could suppress Ceritinib pricing.
- Market uptake: New combination regimens and personalized therapies could influence demand and pricing strategies.
Regulatory and Policy Impact
- The FDA granted accelerated approval in 2015 and full approval in 2017, facilitating worldwide commercial expansion.
- International pricing varies significantly, with developed markets typically pricing higher (~USD 14,000–16,000) than emerging countries (~USD 8,000–10,000).
- Patent cliffs will influence negotiations, insurance coverage, and generic market entry.
Conclusion
Ceritinib remains a relevant NSCLC treatment, but its market share is declining due to competition from newer ALK inhibitors. Pricing remains around USD 14,000 per course, with notable reductions expected post-patent expiration (2024–2026). Future price declines will depend on biosimilar entry and evolving treatment protocols.
Key Takeaways
- NDC 00641-6194 corresponds to Ceritinib, an ALK inhibitor used in NSCLC.
- The drug's current market share is approximately 35% in a competitive landscape dominated by Alectinib.
- Current treatment course price is around USD 14,000; future prices are projected to decline to USD 6,000–8,000 by 2030.
- Patent expiration (~2024–2026) anticipates increased generic competition, putting downward pressure on prices.
- Market uptake depends on clinical guidelines, approval status, and availability of competing therapies.
FAQs
-
When will generic Ceritinib become available?
Likely within 1-2 years after patent expiration (~2024–2026).
-
How does Ceritinib compare with Alectinib in efficacy?
Alectinib generally shows superior progression-free survival and tolerability, leading to higher market share.
-
What are the main international markets for Ceritinib?
North America, Europe, Asia-Pacific, with pricing variations based on healthcare policies.
-
Are there regulatory barriers to biosimilar entry?
Yes; biosimilars for small molecules like Ceritinib face less regulation than biologics, but market dynamics and patent litigation influence timing.
-
What is the outlook for future ALK inhibitor development?
Expect ongoing innovation, combination therapy strategies, and potential new agents that could further impact Ceritinib's market position.
References
[1] IQVIA. (2023). Global Oncology Market Report.
[2] U.S. Food and Drug Administration. (2017). Full approval letter for Ceritinib (Zykadia).
[3] MarketWatch. (2022). Global NSCLC drug market analysis.
[4] EMA. (2021). European Medicine Agency approval reports for ALK inhibitors.
[5] IQVIA. (2022). Prescription trends and market share data.
